Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery.

Plog MS, Guyre CA, Roberts BL, Goldberg M, St George JA, Perricone MA.

Hum Gene Ther. 2006 Jul;17(7):705-16.

PMID:
16839270
2.

Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens.

Perricone MA, Claussen KA, Smith KA, Kaplan JM, Piraino S, Shankara S, Roberts BL.

Mol Ther. 2000 Mar;1(3):275-84.

3.

Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.

Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL.

J Immunol. 1999 Jul 15;163(2):699-707.

4.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE.

J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900.

5.

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA.

J Immunol. 1996 Jan 15;156(2):700-10.

PMID:
8543823
6.

In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.

Linette GP, Shankara S, Longerich S, Yang S, Doll R, Nicolette C, Preffer FI, Roberts BL, Haluska FG.

J Immunol. 2000 Mar 15;164(6):3402-12.

7.

Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR.

Hempel DM, Smith KA, Claussen KA, Perricone MA.

J Immunol Methods. 2002 Jan 1;259(1-2):129-38.

PMID:
11730848
8.

Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.

Zhou WZ, Kaneda Y, Huang S, Morishita R, Hoon D.

Gene Ther. 1999 Oct;6(10):1768-73.

10.

Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines.

Potthoff A, Schwannecke S, Nabi G, Hoffmann D, Grunwald T, Wildner O, Brockmeyer NH, Uberla K, Tenbusch M.

Vaccine. 2009 May 11;27(21):2768-74. doi: 10.1016/j.vaccine.2009.03.001. Epub 2009 Mar 13.

PMID:
19366575
11.

Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy.

Sugimoto M, Watanabe M, Kaku H, Li SA, Noguchi H, Ueki H, Sakaguchi M, Huh NH, Nasu Y, Kumon H.

Oncol Rep. 2012 Nov;28(5):1645-52. doi: 10.3892/or.2012.2001. Epub 2012 Aug 30.

PMID:
22941469
12.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

14.

Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.

Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG.

Gene Ther. 1998 Jul;5(7):975-83.

15.

MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor.

Broder H, Anderson A, Kremen TJ, Odesa SK, Liau LM.

J Neurooncol. 2003 Aug-Sep;64(1-2):21-30.

PMID:
12952283
16.

Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.

Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU.

J Immunother. 2013 May;36(4):238-47. doi: 10.1097/CJI.0b013e3182941813.

PMID:
23603858
17.

Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.

Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.

J Gene Med. 1999 Nov-Dec;1(6):400-6.

PMID:
10753065
18.

Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo.

Wagner SN, Wagner C, Lührs P, Weimann TK, Kutil R, Goos M, Stingl G, Schneeberger A.

J Invest Dermatol. 2000 Dec;115(6):1082-7.

19.

Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Hangalapura BN, Oosterhoff D, Gupta T, de Groot J, Wijnands PG, van Beusechem VW, den Haan J, Tüting T, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD.

Vaccine. 2011 Mar 9;29(12):2313-21. doi: 10.1016/j.vaccine.2011.01.022. Epub 2011 Jan 25.

Supplemental Content

Support Center